ASCO GU 2027: 5 Genitourinary Abstracts That Move Stocks

Every biotech investor screens ASCO and ESMO. Almost no one screens the ASCO Genitourinary Cancers Symposium, and that is exactly where the edge lives. ASCO GU 2027 runs February 11 to 13 at Moscone West in San Francisco, but the trade does not fire at the podium. The abstract submission deadline is October 13, late-breaking data is due November 12, notifications go out in late November, and abstract titles hit the website in early January. Full regular abstracts drop February 8, just three days before the meeting, and late breakers release the morning of their presentation. That puts the positioning window in front of us right now, with the first hard trade date the January title release and the full-data move landing February 8.

This is the one major GU oncology meeting the site has not previewed. Prior previews have covered ESMO, ASH, SITC, ACR, and CTAD. GU oncology is where the money actually sits: it is the one cancer subsector where approvals expand the addressable population instead of reshuffling share, which is laid out in the GU oncology catalysts roundup. Here are five names ranked by stock-moving potential, not by market cap.

1. Arcus (RCUS, $24.97, $3.18B cap): the HIF-2a challenger

Arcus is the highest-beta small cap on the GU board, and it is priced like the market has already written off the kidney bet. The whole bull case is casdatifan, a next-generation HIF-2a inhibitor chasing Merck’s Welireg (belzutifan), the first-in-class HIF-2a that did $716 million in 2025 growing 41% year over year. Casdatifan’s Phase 1/1b ARC-20 data already look better on paper: 15.1 months median progression-free survival and a 45% confirmed response rate in the 100 mg once-daily cohort, versus 12.2 months and 35% in the pooled 121-patient analysis. Those are late-line, heavily pretreated patients. The full breakdown is in the casdatifan ARC-20 analysis.

The reason to watch this meeting specifically is the combination data. On September 22 Arcus held an investor event that added the datasets that matter for Phase 3: casdatifan plus cabozantinib in 43 immunotherapy-experienced patients, the same combination and population as PEAK-1; casdatifan plus zimberelimab in 30 first-line patients on a TKI-free regimen; and a triple of casdatifan plus ipilimumab plus zimberelimab that supports a first-line registrational trial starting in the fourth quarter. The cabozantinib combo is the dress rehearsal for PEAK-1, the Phase 3 trial that fully enrolls at the end of 2026. The benchmark it must beat is Merck’s belzutifan plus cabozantinib, which posted a 70% response rate and 30.3 months median progression-free survival in first-line kidney cancer, the number sized up against casdatifan in the Welireg plus Lenvima analysis.

The re-rate thesis is the spread between the science and the price. Arcus trades at $3.18 billion for a drug that, if it beats Welireg, could be a multi-billion-dollar kidney franchise. A clean combination read at ASCO GU re-rates it toward $4.5 billion to $5 billion. The risk is the mirror image: single-arm Phase 1/1b data does not guarantee Phase 3 success, and Welireg already owns the class. Grade 3 or higher anemia ran at 25% in the 100 mg cohort, a known on-target cost of HIF-2a inhibition. This is a 1% to 2% position, not a core holding.

2. Summit (SMMT, $15.61, $12.45B cap): the platform read-through, not the trade

Summit is the only liquid pure play in GU, but the honest read is that ASCO GU is not where this stock moves. Ivonescimab, the PD-1/VEGF bispecific, launched HARMONi-GU1 in August, a Phase 2/3 trial pitting ivonescimab plus Padcev against Keytruda plus Padcev in first-line metastatic urothelial carcinoma. That is an active-controlled head-to-head against the standard of care, a bold design, but it will not read out for years. The design is detailed in the HARMONi-GU1 coverage.

The GU data point that could surface is the kidney combination. In July Arcus and Summit agreed to add a casdatifan plus ivonescimab cohort to ARC-20, a TKI-sparing pairing that hits HIF-2a, PD-1, and VEGF at once. Early data from that cohort would be the first signal the bispecific extends beyond lung cancer. But the catalyst that actually reprices Summit is the November 14 PDUFA for ivonescimab in non-small cell lung cancer, which resolves nearly three months before this meeting. By the time ASCO GU opens, that coin flip is already decided. Rank Summit for the platform read-through, not as a GU trade.

3. Telix (TLX, $11.45, $3.89B cap): the radiopharma pure play with a therapy catalyst

Telix is the cleanest way to own radiopharma growth without the mega-cap dilution, and it has a genuine GU therapy readout coming. TLX591-Tx, its lutetium-177 PSMA radio antibody-drug conjugate for metastatic castration-resistant prostate cancer, presented Phase 3 Part 1 safety and dosimetry data as a late-breaker at ASCO 2026: 36 patients across three standard-of-care combinations, acceptable tolerability, no new safety signals, and Part 2, the 2:1 randomized expansion, now underway. The differentiator is that TLX591-Tx is hepatically excreted, which spares the kidneys and salivary glands the toxicity that limits Pluvicto. The full isotope-moat picture is in the radiopharma deep dive.

The business is not a science project. Illuccix, its PSMA-PET imaging agent, generated $247 million in Q2, up 21%, on a path to roughly $950 million to $970 million for the year. At $3.89 billion you are paying about 4x forward sales for the imaging franchise plus a free option on the therapy pipeline. The screen at ASCO GU is TLX591-Tx Part 2 data and TLX250, the renal cancer program. A clean therapy signal re-rates Telix toward $5 billion; a safety stumble in Part 2 shaves the option value but leaves the imaging base intact.

4. Aura Biosciences (AURA, $6.00, $622M cap): the NMIBC lottery ticket

Aura is the out-of-the-money call in the group. AU-011, its virus-like drug conjugate, has shown multiple clinical complete responses in a Phase 1/2 trial in non-muscle-invasive bladder cancer. The catch, which is flagged in the GU roundup, is that the registrational Phase 3 trial, CoMpass, is in early-stage choroidal melanoma, not bladder. So any AU-011 bladder data at ASCO GU is a Phase 1/2 signal, not a registrational result.

At $622 million this is a platform option, not an investment. If the NMIBC data looks clean and the company commits to a registrational path, it re-rates hard from a microcap base. If the data is mixed, the valuation drifts toward cash. Only for risk capital.

5. The read-through: the PSMA radioligand class expansion

The fifth slot is a theme, not a ticker, because the biggest GU story of the next two years does not belong to a small cap. Novartis’s Pluvicto moved from metastatic castration-resistant to hormone-sensitive prostate cancer on July 31, roughly quadrupling the eligible population, and it is already a $2.6 billion run rate growing 43%. The next-generation 225Ac-PSMA-617 alpha therapy reads out in 2027 to 2028. That value accrues to the isotope supply chain and to Telix, not to a $300 billion Novartis. The Pluvicto franchise analysis has the full math. Screen the Pluvicto presentations for what they imply about isotope demand and the PSMA class, then trade the pure play.

The mega-cap filter

The headline GU updates that will dominate this meeting move zero basis points. Merck’s Welireg plus Lenvima kidney combination was already approved September 24, ten days early, after LITESPARK-011 cut the risk of progression or death by 26% versus cabozantinib. Merck’s Padcev plus Keytruda bladder combination was approved July 10, five weeks early, on KEYNOTE-B15. Pfizer’s Talzenna plus XTANDI priority review for HRR-mutated prostate cancer carries a PDUFA around late January 2027, which means it is decided before ASCO GU opens. Bayer’s radium-223 is a declining franchise. These are real approvals on real data, and none of them move a $141 billion to $374 billion market cap. The Padcev plus Keytruda MIBC approval registered as noise, exactly as it should have.

The playbook

The trade fires at abstract release, not the podium. Abstract titles hit early January, full regular abstracts drop February 8, three days before the meeting, and late breakers land the morning of presentation. The full playbook is in the conference trading guide: enter on the release, size each binary at 1% to 2% of the portfolio, expect implied volatility crush after the release, and apply the 24-hour rule. Do not hold through the meeting for a reaction that already happened.

The verdict

Two of these names actually re-rate on GU data, and they are not the ones the headlines will feature. Arcus is the reward-per-dollar play: a $3.18 billion single-asset kidney bet where one clean casdatifan combination read can justify a move toward $5 billion. Telix is the safer version of the same idea: a revenue-generating radiopharma pure play where the therapy data is a free option on top of a real imaging business. Summit is a platform read-through whose dominant catalyst, the November 14 PDUFA, is already decided before ASCO GU opens. Aura is a lottery ticket. Screen the mega-caps for what their data means for the class, then buy Arcus and Telix, the two names where a single GU abstract still moves the stock.

Sources: ASCO GU 2027 key dates.